Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years
Eli Lilly was supposed to mark this year with the launch of a new blockbuster medicine for rheumatoid arthritis — waging a commercial war with some …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
